Dr. Christopher L. Moertel, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
2450 Riverside Ave., East Building, Ninth Floor
Minneapolis, MN 55454
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 14
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MN license 31321
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 14
- Services billed
- 24
- Patients’ average age
- 49
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Koselugo (selumetinib sulfate) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 28 payments worth $31,674 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $16,366 |
|---|---|
| Springworks Therapeutics, Inc. | $15,308 |
| Compensation for services other than consulting (speaking, faculty) | $24,980 |
|---|---|
| Consulting Fee | $3,810 |
| Travel and Lodging | $2,695 |
| Food and Beverage | $189 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Springworks Therapeutics, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $10,160 |
| Alexion Pharmaceuticals, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) KOSELUGO · Oncology Company’s descriptionSpeaker Fee | $6,240 |
| Alexion Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,240 |
| Springworks Therapeutics, Inc. Apr 11, 2025 | Consulting Fee GOMEKLI · NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | $3,810 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) KOSELUGO · Oncology Company’s descriptionSpeaker Fee | $2,340 |
| Springworks Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ · in-kind | $584 |
| Alexion Pharmaceuticals, Inc. Mar 24, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $497 |
| Springworks Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ · in-kind | $414 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to Omaha, NE · in-kind Company’s descriptionSpeaker Expenses | $387 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $251 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,240 |
| Springworks Therapeutics, Inc. Apr 11, 2025 | Consulting Fee GOMEKLI · NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | $3,810 |
| Alexion Pharmaceuticals, Inc. Apr 11, 2025 | Travel and Lodging travel to St. Paul, MN | $32.56 |
| Alexion Pharmaceuticals, Inc. Apr 11, 2025 | Travel and Lodging travel to Las Vegas, NV | $29.30 |
| Alexion Pharmaceuticals, Inc. Apr 11, 2025 | Travel and Lodging travel to Minneapolis, MN | $13.72 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $251 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Las Vegas, NV | $40.96 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Las Vegas, NV | $35.92 |
| Springworks Therapeutics, Inc. Apr 2, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ | $135 |
| Springworks Therapeutics, Inc. Apr 2, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ | $76.94 |
| Springworks Therapeutics, Inc. Apr 2, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ | $70.10 |
| Springworks Therapeutics, Inc. Apr 2, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ | $25.98 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) KOSELUGO · Oncology Company’s descriptionSpeaker Fee | $2,340 |
| Springworks Therapeutics, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $10,160 |
| Alexion Pharmaceuticals, Inc. Mar 24, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s descriptionSpeaker Expenses | $497 |
| Springworks Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ · in-kind | $584 |
| Springworks Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to FAIRFIELD, NJ · in-kind | $414 |
| Alexion Pharmaceuticals, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) KOSELUGO · Oncology Company’s descriptionSpeaker Fee | $6,240 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to Omaha, NE · in-kind Company’s descriptionSpeaker Expenses | $387 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to St Paul, MN | $32.56 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to Omaha, NE | $30.00 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to Omaha, NE | $27.06 |
| Alexion Pharmaceuticals, Inc. Jan 24, 2025 | Travel and Lodging KOSELUGO · Oncology · travel to Omaha, NE | $13.17 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $169,984 in research payments for these studies, mostly to the institutions running them.
- An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Novartis Pharmaceuticals Corporation - MEK-NF-201
Springworks Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.